|
|
Company Management
Linda F. PowersChief Executive Officer
Ms. Powers has served as Chairman of NWBT for the last 4 years, and brings more than 25 years’
experience in corporate transactions and operations, including more than a decade specializing in
building biotech companies through Toucan Capital. Ms. Powers is particularly well known for
her experience in building biotech companies that are developing cell therapies, including both
immune cell therapies (such as NWBT’s DCVax®) and adult stem cell therapies. Such products --
consisting of living human cells -- require fundamentally different manufacturing, storage,
distribution and handling than do pharmaceutical drugs (“pills in bottles”). Such living cell
products also involve different clinical and regulatory requirements, and different business and
cost/pricing models, than traditional drugs. The cell therapy companies which Ms. Powers has
been involved in building over the last decade, both in the US and abroad (in Asia, Europe and
Israel), are at the forefront of clinical trials and early commercialization. Ms. Powers has served
for years on a number of related boards, including the M2Gen Board of the Moffitt Cancer Center,
the Board of the Trudeau Institute (a world leader in immunology research) and others. As
Chairman of NWBT, she has brought her lengthy experience to bear in helping to shape NWBT’s
overall strategy and programs. As CEO, she will now undertake operational responsibilities in
addition to continuing her duties as Chairman.
Anthony Maida, Ph.D.Chief Operating Officer
As the newest member of the management team, Dr. Maida brings more than 20 years’ experience
in building oncology companies, with expertise in the business and financial aspects, the clinical
and regulatory aspects, and the underlying science. Over these two decades, Dr. Maida has held
positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised
nearly $200 million in financings for these oncology companies. Among these experiences, he
served for a period as CEO of CancerVax, an early leader in cancer vaccines. In that role, he
raised the company’s first $30 million of funding, and was responsible for conducting multihundred
patient, multi-center clinical trials with the company’s cancer vaccines. Prior to joining
NWBT as COO, Dr. Maida was serving as global head of Oncology for a leading contract research
organization that manages clinical trials in the US and internationally.
Dr. Maida has been responsible for negotiating partnering and licensing transactions with many
premier pharmaceutical companies and academic centers of excellence, including, among others,
Eli Lilly, Novartis, RCT Corporation, Astra Zeneca, Pfizer, Bristol Myers Squibb, MD Anderson,
Yale University, Stanford University, University of California San Francisco and Davis, and the
Wistar Institute. Dr. Maida’s already strong scientific expertise was further strengthened as he
recently completed and in 2010 received a PhD in Tumor Immunology. On the financial front, Dr.
Maida has served for years as a key adviser to many large institutional investors for their oncology
investments. Dr. Maida serves on several boards in the oncology field, including Spectrum
Pharmaceuticals and others. Earlier in his career, Dr. Maida served for a number of years as the
Chief Financial Officer of a large public company’s subsidiary and Senior Financial Controller of
a $1.7 billion division of that company (Lockheed).
Les GoldmanSenior Vice President, Business Development
Mr. Les Goldman was a partner at the law firm of Skadden, Arps for over 30 years, specializing in
a wide array of advanced technologies and their commercialization. He helped build one of the
preeminent global practices in this area. He was responsible for advising on financing, regulatory
strategies, and public outreach relating to his clients’ development of numerous cutting edge
technologies, bringing to bear a diverse range of deal-making skills. He has taken a special early
retirement from Skadden, Arps to enable him to undertake an executive role at NWBT. Mr.
Goldman also serves as an advisor to a number of other breakthrough technology companies. In
addition, for 8 years, Mr. Goldman has served as Chairman of the Board of a group of TV Stations
in 4 mid-size cities across the country. Mr. Goldman is joining NWBT as Senior VP Business
Development.
Alton L. Boynton, Ph.D.Chief Scientific Officer
Dr. Alton Boynton is the scientific founder of NWBT, and was the first in the world to conduct a
clinical trial with dendritic cells – the master cells of the immune system, which are the cells used
in NWBT’s DCVax® products. During the 1990s, when little was known about dendritic cells
and their roles, Dr. Boynton’s research lab was an early leader in identifying the important clinical
capabilities of the dendritic cells and their potential for fighting cancer. Within this academic
setting, during the 1990s Dr. Boynton treated over 100 prostate cancer patients with the DCVax®
technology, prior to commencing formal clinical trials in the Company. Since that time,
Dr. Boynton served as the Chief Scientific Officer of the Company until 2007, at which time he
became CEO. Prior to founding NWBT, Dr. Boynton headed the Molecular Oncology research
lab at the Pacific Northwest Research Foundation (the original foundation of Bill Hutchinson, from
which the Fred Hutchinson Cancer Center was spun off), focusing on dendritic cells, and he
established and headed the Molecular Oncology research department at Northwest Hospital in
Seattle (where the first clinical trial with dendritic cells took place in 1995). Earlier in his career,
Dr. Boynton was Associate Director of the University of Hawaii Cancer Center, and a professor of
Genetics and Molecular Biology. He has authored over 150 peer-reviewed research publications,
and is the inventor on numerous issued and pending patents relating to dendritic cells. Dr.
Boynton is resuming his position as Chief Scientific Officer of NWBT.
Marnix L. Bosch, Ph.D.Chief Technical Officer
Dr. Bosch joined NWBT in 2000, and has been serving as Chief Technical Officer for a number of
years. In this capacity, he plays a key role in the preparation and submission of the Company’s
regulatory applications, as well as ongoing development of the Company’s product lines, and
ongoing development and/or acquisition of new technologies. Dr. Bosch led the process of
designing the protocols, and managed the successful preparation and submission of the Company’s
INDs (applications for FDA approval to conduct clinical trials), for prostate cancer, brain cancer
and five other cancers. He also led the processes for other regulatory submissions in both the US
and abroad (including the successful applications for orphan drug status in both the US and Europe
for DCVax-L® for brain cancer). He spearheaded the development of the Company’s
manufacturing and quality control processes, and is working with the Company’s contract
manufacturer, Cognate BioServices, on next-generation further development of these processes.
Prior to joining NWBT in 2000, Dr. Bosch worked at the Dutch National Institutes of Health
(RIVM) as head of the Department of Molecular Biology, as well as in academia as a professor of
Pathobiology. He has authored more than 40 peer-reviewed research publications in immunology
and virology, and is an inventor on several patent applications on dendritic cell product
manufacturing. Dr. Bosch is continuing in his capacity as Chief Technical Officer of NWBT.
|
